

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

**Cais Rhyddid Gwybodaeth / Freedom of Information request**  
**Ein Cyf / Our Ref: 23-B-038**

Please note that we have provided this information for the period November 2022 to January 2023

**You asked:**

**1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	Unable to split Abemaciclib patients – 8 patients on all combinations
Abemaciclib + Fulvestrant	
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	0
Atezolizumab + Nab-paclitaxel/Paclitaxel	<5
Capecitabine as a single agent	12
Eribulin as a single agent or in combination	7
Everolimus + Exemestane	<5 patients on Everolimus – Exemestane is not prescribed on our system so unable to provide information on combination
Fulvestrant as a single agent	19 (unable to state if combined with aromatase inhibitors)
Lapatinib	0
Neratinib	0
PARP inhibitors (Olaparib/Talazoparib)	0
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	Unable to split Palbociclib patients – 33 patients on all combinations
Palbociclib + Fulvestrant	
Pembrolizumab	0
Platinum (e.g. carboplatin or cisplatin) as a single agent	8
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	Unable to split Ribociclib patients – 12 patients on all combinations



Ribociclib + Fulvestrant	
Sacituzumab Govitecan	0
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	47
Taxane and/or Anthracycline in combination	52
Trastuzumab as a single agent or in combination	23
Trastuzumab emtansine	12
Trastuzumab deruxtecan	5
Any other active systemic anti-cancer therapy	<5

**2. Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:**

- **early/locally advanced breast cancer (Stages 1 to 3B)**
- **advanced/metastatic breast cancer (Stages 3C and 4)**

I can confirm that this information is not recorded by staging of the cancer. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

